<?xml version="1.0" encoding="UTF-8"?>
<p id="P51">Oseltamivir carboxylate, the active drug metabolite, selectively blocks viral neuraminidase, thereby preventing the release of virus from infected cells.
 <sup>
  <xref ref-type="bibr" rid="R98">98</xref>
 </sup> Oseltamivir is approved for the treatment of children (â‰¥1 year) and adults with influenza A or B viral infections.
 <sup>
  <xref ref-type="bibr" rid="R98">98</xref>
 </sup> Treatment should start within 48 hours of disease onset and continue for 5 days. Oseltamivir is as effective as the other neuraminidase inhibitor, zanamivir, in reducing the febrile period during infection with influenza A (H1N1), influenza A (H3N2), and influenza B virus.
 <sup>
  <xref ref-type="bibr" rid="R99">99</xref>
 </sup>
</p>
